Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$2.4B
Enterprise value$1.9B
Revenue$22.5M −50.6%
ROIC-116.7%
EPS, diluted$-1.72 +32.8%
Modern Valuation (EOD)
Market Cap$2.4B
Enterprise Value$1.9B
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales83.08
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book3.45
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield-8.6%
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh—
EPS (diluted)$-1.72
Compounder & Returns
Rule of 40—
ROIC-116.7%
Cash ROIC (CROIC)—
GP / Assets—
ROE-29.7%
ROA-26.4%
Gross Margin—
Oper. Margin-1002.9%
Net Margin-902.1%
FCF Margin—
True FCF Margin—
Quality & Dilution
Cash Conversion—
Accrual Ratio−7.2%
SBC % of FCF—
SBC % of Rev264.1%
Reinvest. Rate—
Sales Growth Y/Y−50.6%
Sales 3Y CAGR−39.7%
EPS Growth Y/Y+32.8%
FCF Growth Y/Y—
FCF 3Y CAGR—
Share Change Y/Y+25.5%
Balance Sheet & Scale
Revenue (FY)$22.5M
Gross Profit (FY)—
Oper. Income (FY)$-225.7M
GAAP Net Income$-203.0M
True FCF (ex-SBC)—
Cash & Equiv$490.0M
Total Debt—
Net Cash (Debt)$490.0M
Net Cash % MCap+20.8%
Debt / FCF (yrs)—
Current Ratio7.88119.93M sh
Price & Technicals (EOD)
Perf Week−2.30%
Perf Month−9.21%
Perf Quarter−30.00%
Perf Half Y−45.41%
Perf YTD−34.66%
SMA 20 Dist−1.69%$19.85
SMA 50 Dist−7.87%$21.18
SMA 100 Dist−22.28%$25.10
Window High−50.72%$39.59
Window Low+3.28%$18.89
RSI (14) · Vol44.469%v
Income Distribution & Cash Flow ConversionHow every dollar of NAMS revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)
FY2022
FY2023
FY2024
FY2025
YoY Δ
3Y CAGR
Trend
Income Statement
Revenue ▸
$102.7M
$14.1M
$45.6M
$22.5M
−50.6%
−39.7%
Research & Development (R&D)
$86.7M
$159.4M
$151.4M
$141.8M
−6.3%
+17.8%
Selling, General & Admin (SG&A)
$19.5M
$37.6M
$70.4M
$106.4M
+51.0%
+76.0%
Total Operating Expenses
$106.3M
$197.1M
$221.9M
$248.2M
+11.9%
+32.7%
Operating Income (EBIT) ▸
$-3.6M
$-183.0M
$-176.3M
$-225.7M
−28.0%
—
Interest Expense
$287,000
—
—
$287,000
—
+0.0%
Income Tax Expense
—
$27,000
$-1,000
$-1,000
+0.0%
—
GAAP Net Income ▸
$-22.6M
$-177.0M
$-242.0M
$-203.0M
+16.1%
—
Diluted EPS ▸
$-1.19
$-2.15
$-2.56
$-1.72
+32.8%
—
Diluted Shares
19.0M
82.2M
94.4M
118.4M
+25.5%
+84.1%
Balance Sheet
Cash & Equivalents
$423.1M
$340.4M
$771.7M
$490.0M
−36.5%
+5.0%
Total Current Assets
$478.0M
$346.8M
$863.4M
$675.7M
−21.7%
+12.2%
Total Assets
$478.5M
$347.1M
$864.6M
$769.3M
−11.0%
+17.1%
Total Current Liabilities
$36.1M
$49.9M
$106.9M
$85.8M
−19.8%
+33.5%
Total Liabilities
$48.4M
$58.7M
$107.1M
$85.9M
−19.9%
+21.0%
Stockholders' Equity
$430.1M
$288.4M
$757.5M
$683.4M
−9.8%
+16.7%
Net Cash / (Net Debt)
$423.1M
$340.4M
$771.7M
$490.0M
−36.5%
+5.0%
Invested Capital
$6.9M
$-52.1M
$-14.2M
$193.4M
+1458.1%
+203.2%
Cash Flow & Capital Allocation
Operating Cash Flow (OCF) ▸
$10.7M
$-141.2M
$-158.6M
$-147.8M
+6.8%
—
Depreciation & Amortization (D&A)
$9,000
$49,000
$113,000
$220,000
+94.7%
+190.2%
Stock-Based Compensation (SBC)
$4.1M
$24.6M
$33.6M
$59.4M
+76.8%
+143.5%
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.
What happened · big days
13 big days in a year, and what we hold on each
A big day is a close more than 6.58% from the one before, three times NAMS’s median day (2.19%). On 0 of the 13, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.
every other trading daya big day, numbered in the list below±6.58%Hover a bar for its day. Click a big day to open it.
Shaded: since our stories began, Jun 10. Tap a bar for its day.
#DayNAMSWhat we hold that dayGroup (median of 4) · each
1 Dec 3, 2025−7.33%
Before our storiesgroup +0.6%, did not move with it
1Dec 3, 2025−7.33%
Before our stories
+0.6% did not move with itLLY −1.2 · JNJ −0.0 · MRK +1.2 · ABBV +2.6
2 Feb 6, 2026+6.99%
Before our storiesgroup +1.9%, did not move with it
2Feb 6, 2026+6.99%
Before our stories
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.8 · JNJ +0.9
3 Mar 2, 2026−7.42%
Before our storiesgroup −0.9%, did not move with it
3Mar 2, 2026−7.42%
Before our stories
−0.9% did not move with itLLY −3.2 · MRK −1.9 · JNJ +0.1 · ABBV +0.9
4 Mar 3, 2026−7.39%
Before our storiesgroup −0.9%, did not move with it
4Mar 3, 2026−7.39%
Before our stories
−0.9% did not move with itMRK −1.3 · LLY −1.0 · JNJ −0.7 · ABBV −0.2
5 Mar 31, 2026+9.14%
Before our storiesgroup +1.9%, did not move with it
5Mar 31, 2026+9.14%
Before our stories
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
6 May 7, 2026+12.46%
Resultsgroup −1.1%, did not move with it
6May 7, 2026+12.46%
ResultsFirst close after the May 7 results filing
−1.1% did not move with itJNJ −0.9 · MRK −1.1 · ABBV −1.1 · LLY −1.2
7 May 8, 2026+11.13%
Before our storiesgroup −0.7%, did not move with it
7May 8, 2026+11.13%
Before our stories
−0.7% did not move with itJNJ −0.5 · ABBV −0.6 · MRK −0.8 · LLY −2.7
8 Jul 21, 2026+9.00%
Nothing on NAMSgroup +1.3%, did not move with it
8Jul 21, 2026+9.00%
Nothing on NAMSNo NAMS story, brief or results filing in our record that day
+1.3% did not move with itLLY +2.5 · MRK +1.5 · ABBV +1.1 · JNJ +0.7
9 Jul 28, 2026−7.41%
Nothing on NAMSgroup +1.4%, did not move with it
9Jul 28, 2026−7.41%
Nothing on NAMSNo NAMS story, brief or results filing in our record that day
+1.4% did not move with itJNJ +0.3 · MRK +0.8 · LLY +1.9 · ABBV +2.5
10 Sep 9, 2026−11.08%
Nothing on NAMSgroup −0.3%, did not move with it
10Sep 9, 2026−11.08%
Nothing on NAMSNo NAMS story, brief or results filing in our record that day
−0.3% did not move with itJNJ −0.8 · MRK −0.6 · LLY +0.0 · ABBV +0.9
11 Oct 23, 2026−8.67%
Nothing on NAMSgroup −1.4%, did not move with it
11Oct 23, 2026−8.67%
Nothing on NAMSNo NAMS story, brief or results filing in our record that day
−1.4% did not move with itLLY −2.5 · JNJ −1.4 · MRK −1.3 · ABBV +0.2
12 Nov 5, 2026−9.75%
Nothing on NAMSgroup −2.3%, did not move with it
12Nov 5, 2026−9.75%
Nothing on NAMSNo NAMS story, brief or results filing in our record that day
−2.3% did not move with itLLY −3.8 · MRK −2.3 · ABBV −2.2 · JNJ −1.4
13 Nov 11, 2026+8.03%
Nothing on NAMSgroup +0.1%, did not move with it
13Nov 11, 2026+8.03%
Nothing on NAMSNo NAMS story, brief or results filing in our record that day
+0.1% did not move with itABBV +0.4 · LLY +0.3 · JNJ −0.1 · MRK −0.6
A story on the same day is not a cause, and a group move is not proof either. Group: the median of LLY, JNJ, ABBV and MRK that day, the largest companies in NAMS’s SEC industry; “moved with NAMS” means the same direction and at least half the size.
What’s next · results
Before the next report: what the first day after the last four did
Six trading days after each results filing (SEC 8-K, Item 2.02). NAMS reports before the open, so day 1 is that day’s close. 2 of 4 times, day 6 ended on the same side as day 1.
Reported Nov 5, 2025
day 1+4.37%day 6+4.87%
Reported Feb 18, 2026
day 1+1.48%day 6−0.65%
Reported May 7, 2026
day 1+12.46%day 6+19.01%
Reported Aug 5, 2026
day 1−0.47%day 6+1.02%
Next report: expected early NovemberEstimated from the dates of its last four results filings. Not announced. Since the Aug 5 report: −28.35%. Four reports is a small sample.
Each line is NAMS’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.
Same industry
NAMS against four drug peers, a year at 100
NAMS is down 48.4% in a year. Merck is up 40.9%, Johnson & Johnson 33.7%, Eli Lilly 30.5% and AbbVie 21.0%. All four did more. Weekly closes, Nov 21, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.
End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in NAMS’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.